These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 30419087)

  • 1. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.
    Kern S; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Waern M; Hagen CE; van Harten AC; Knopman DS; Jack CR; Petersen RC; Mielke MM
    JAMA Neurol; 2019 Feb; 76(2):187-193. PubMed ID: 30419087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study.
    Rådestig MA; Skoog J; Zetterberg H; Skillbäck T; Zettergren A; Sterner TR; Fässberg MM; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
    J Alzheimers Dis; 2023; 91(1):291-303. PubMed ID: 36617786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin.
    Mielke MM; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Vemuri P; Machulda MM; Graff-Radford J; Knopman DS; Jack CR; Petersen RC; Kern S
    Alzheimers Dement; 2019 Nov; 15(11):1437-1447. PubMed ID: 31668594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.
    Mielke MM; Przybelski SA; Lesnick TG; Kern S; Zetterberg H; Blennow K; Knopman DS; Graff-Radford J; Petersen RC; Jack CR; Vemuri P
    Alzheimers Dement; 2021 May; 17(5):801-812. PubMed ID: 33663022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
    Pereira JB; Westman E; Hansson O;
    Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
    Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
    Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer's disease.
    Knudtzon SL; Nordengen K; Grøntvedt GR; Jarholm J; Eliassen IV; Selnes P; Pålhaugen L; Espenes J; Gísladóttir B; Waterloo K; Fladby T; Kirsebom BE
    Neurobiol Aging; 2024 Sep; 141():74-84. PubMed ID: 38838442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds.
    Skoog I; Kern S; Najar J; Guerreiro R; Bras J; Waern M; Zetterberg H; Blennow K; Zettergren A
    J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):983-990. PubMed ID: 33512503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics.
    Van Harten AC; Wiste HJ; Weigand SD; Mielke MM; Kremers WK; Eichenlaub U; Batrla-Utermann R; Dyer RB; Algeciras-Schimnich A; Knopman DS; Jack CR; Petersen RC
    Neurology; 2020 Jul; 95(3):e256-e267. PubMed ID: 32591471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurogranin as a predictor of memory and executive function decline in MCI patients.
    Headley A; De Leon-Benedetti A; Dong C; Levin B; Loewenstein D; Camargo C; Rundek T; Zetterberg H; Blennow K; Wright CB; Sun X;
    Neurology; 2018 Mar; 90(10):e887-e895. PubMed ID: 29429972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
    Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
    JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology.
    Shir D; Mielke MM; Hofrenning EI; Lesnick TG; Knopman DS; Petersen RC; Jack CR; Algeciras-Schimnich A; Vemuri P; Graff-Radford J
    J Alzheimers Dis; 2023; 92(3):887-898. PubMed ID: 36806507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.